Today, sepsis management has become a key concern for hospital executives. Sepsis is responsible for 6 million deaths worldwide per year 1. It is estimated that is costs almost €30,000 to treat sepsis in the ICU 2 and the problem is growing – it is now one of the top 5 causes of hospitalization in age groups over 18.3*‡
Benefits of sepsis management programs: There are many motivators for hospital executives to implement sepsis and stewardship programs:
- Reduction in mortality and morbidity for patients
- Adherence to national regulatory and legal standards
- Shortened lengths of stay, reduction in readmissions, and improved patient flow
- Better management of variable hospital costs, including pharmacy supplies, lab testing, and blood culture bottles
- Reduction in rates of C. diff
- Defense against drug resistance pathogens at the facility3
Drug resistance is becoming an increasing concern among infectious disease specialists. The Journal of Infection Control and Hospital Epidemiology published a November 2018 letter to the editor by Burnham JP and colleagues, that the true burden of deaths due to multidrug-resistant organisms (MDRO) is much higher than reported by the CDC, which estimates 23,000 deaths per year. In this publication, investigators cite a low-end figure of 153,113 deaths due to MDRO’s, a number that is almost 7-fold higher than CDC estimates.4,6,7,8
Leading hospitals report faster targeted therapy, reduced length of stay, and cost savings
Faster targeted therapy, reduced length of stay, and cost savings: The key for sepsis management is time to effective therapy. Faster targeted treatment means shorter lengths of stay, reductions in ineffective therapy, and better survival rates.
Rapid diagnostics within hours: T2Direct Diagnostics can improve sepsis protocols. It is the first and only FDA-cleared and CE-marked system to identify deadly sepsis-causing pathogens directly from whole blood without the need to wait for blood culture. The T2Bacteria® and T2Candida® Panels deliver faster, easier, and more accurate test results in 3 to 5 hours, getting patients on the right treatment earlier and positively impacting patient care and hospital costs.
- Enhanced accuracy and speed: A study conducted at Gemelli Hospital in Rome, Italy, reported that T2Bacteria delivered positive results more than 4.5 times faster with excellent accuracy. 5
- Faster targeted therapy for patients: Henry Ford Health System and Lee Health demonstrated faster targeted therapy by 44 hours and 28 hours respectively for patients with sepsis-causing bloodstream infections.4,6
- Reduced hospital and ICU lengths of stay: Henry Ford and Lee Health also reported reduced overall length of stay by 4 days and 7 days, respectively.7,8
- Improved stewardship and pharmacy savings: The accuracy of T2Direct Diagnostics gives clinicians the confidence to de-escalate unnecessary antimicrobials drugs. Huntsville Hospital (case study) reported pharmacy savings that more than covered the cost of testing all patients with T2Direct Diagnostics.9
* Current data suggest that the true burden of deaths due to multidrug-resistant organisms (MDROs) is much higher than previously reported, with 153,113 to 162,044 U.S. deaths in 2010 attributed to MDROs, a number that is more than 6 times higher than previous CDC estimates.10
‡ Read T2 Biosystems CEO John McDonough’s overview on sepsis management today.
Connect us with your Hospital Administration for an economic evaluation!